{"id":"cggv:f52993aa-ddee-483d-b15e-dbf21608d5a9v1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:f52993aa-ddee-483d-b15e-dbf21608d5a9_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10005","date":"2020-09-01T00:00:00Z","role":"Publisher"},{"id":"cggv:f52993aa-ddee-483d-b15e-dbf21608d5a9_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10005","date":"2018-07-18T12:50:00.560Z","role":"Approver"}],"evidence":[{"id":"cggv:f52993aa-ddee-483d-b15e-dbf21608d5a9_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:f52993aa-ddee-483d-b15e-dbf21608d5a9_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:06ec187e-90ad-417c-8692-e49676f5342b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:67ad3e25-582d-44da-be2d-e618cdedbde5","type":"Finding","demonstrates":{"id":"cg:GeneExpressionA"},"dc:description":"Showed the expression of mouse Nav1.6 is high in the brain and spinal cord and extremely low to absent in the heart. Lorincz 2010:  Showed imm8unolocalization of Nav1.6 to the AIS in neurons and well as immunogold of Nav1.6/ SCN8A localizing it to the nodes of Ranvier and AIS on neurons. Wagnon et al., 2015:  shows expression of the mutant N1768D in brains of the knockin mice.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/9828131","type":"dc:BibliographicResource","dc:abstract":"The voltage-gated sodium channel SCN8A is associated with inherited neurological disorders in the mouse that include ataxia, dystonia, severe muscle weakness, and paralysis. We report the complete coding sequence and exon organization of the human SCN8A gene. The predicted 1980 amino acid residues are distributed among 28 exons, including two pairs of alternatively spliced exons. The SCN8A protein is evolutionarily conserved, with 98.5% amino acid sequence identity between human and mouse. Consensus sites for phosphorylation of serine/threonine and tyrosine residues are present in cyoplasmic loop domains. The polymorphic (CA)n microsatellite marker D12S2211, with PIC = 0.68, was isolated from intron 10C of SCN8A. Single nucleotide polymorphisms in intron 19 and exon 22 were also identified. We localized SCN8A to chromosome band 12q13.1 by physical mapping on a YAC contig. The cDNA clone CSC-1 was reported by others to be a cardiac-specific sodium channel, but sequence comparison demonstrates that it is derived from exon 24 of human SCN8A. The genetic information described here will be useful in evaluating SCN8A as a candidate gene for human neurological disease.","dc:creator":"Plummer NW","dc:date":"1998","dc:title":"Exon organization, coding sequence, physical mapping, and polymorphic intragenic markers for the human neuronal sodium channel gene SCN8A."},"rdfs:label":"Expression Functional"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":2,"dc:description":"Given the restricted expression in neurons, and the multiple lines of evidence, assigning max points of 2"},{"id":"cggv:6d0e38de-791a-4036-a6a4-ee2d9471f5da","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:e4a4a148-f601-4aed-9e56-88ed87e2534f","type":"Finding","demonstrates":{"id":"obo:MI_0915"},"dc:description":"C-terminus of Nav1.6 interacted with Navb1 (Scn1b)","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/26900580","type":"dc:BibliographicResource","dc:abstract":"The early infantile epileptic encephalopathy type 13 (EIEE13, OMIM #614558) results from de novo missense mutations of SCN8A encoding the voltage-gated sodium channel Nav1.6. More than 20% of patients have recurrent mutations in residues Arg1617 or Arg1872. Our goal was to determine the functional effects of these mutations on channel properties.","dc:creator":"Wagnon JL","dc:date":"2016","dc:title":"Pathogenic mechanism of recurrent mutations of SCN8A in epileptic encephalopathy."},"rdfs:label":"Function PI"}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2},{"id":"cggv:f52993aa-ddee-483d-b15e-dbf21608d5a9_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:dba9ac9d-8782-4db1-8bec-b48c8d3d48ab","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:5786dda6-5eea-4f9f-9736-4a2fc65f03ed","type":"FunctionalAlteration","dc:description":"Hippocampal neurons (rat) transfected with mutant Nav1.6 exhibited increased spontaneous firing and increased frequency of action potentials","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/22365152","type":"dc:BibliographicResource","dc:abstract":"Individuals with severe, sporadic disorders of infantile onset represent an important class of disease for which discovery of the underlying genetic architecture is not amenable to traditional genetic analysis. Full-genome sequencing of affected individuals and their parents provides a powerful alternative strategy for gene discovery. We performed whole-genome sequencing (WGS) on a family quartet containing an affected proband and her unaffected parents and sibling. The 15-year-old female proband had a severe epileptic encephalopathy consisting of early-onset seizures, features of autism, intellectual disability, ataxia, and sudden unexplained death in epilepsy. We discovered a de novo heterozygous missense mutation (c.5302A>G [p.Asn1768Asp]) in the voltage-gated sodium-channel gene SCN8A in the proband. This mutation alters an evolutionarily conserved residue in Nav1.6, one of the most abundant sodium channels in the brain. Analysis of the biophysical properties of the mutant channel demonstrated a dramatic increase in persistent sodium current, incomplete channel inactivation, and a depolarizing shift in the voltage dependence of steady-state fast inactivation. Current-clamp analysis in hippocampal neurons transfected with p.Asn1768Asp channels revealed increased spontaneous firing, paroxysmal-depolarizing-shift-like complexes, and an increased firing frequency, consistent with a dominant gain-of-function phenotype in the heterozygous proband. This work identifies SCN8A as the fifth sodium-channel gene to be mutated in epilepsy and demonstrates the value of WGS for the identification of pathogenic mutations causing severe, sporadic neurological disorders.","dc:creator":"Veeramah KR","dc:date":"2012","dc:title":"De novo pathogenic SCN8A mutation identified by whole-genome sequencing of a family quartet affected by infantile epileptic encephalopathy and SUDEP."},"rdfs:label":"FA Non-patient Cells"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.5},{"id":"cggv:f52993aa-ddee-483d-b15e-dbf21608d5a9_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:1b5f6975-8794-4773-9ed3-a8a799ea1578","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:55012ff4-fb23-4292-900d-c47903df3f71","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"Generated genetic locus specific knockin mice of the EIEE patient derived mutaiton N1768D, using TALON technology. These mice express the mutation in a heterozygous state, and are not a transgenic overxpression. The heterozygous mice develop seizures after 3 months of age, and eventually die from SUDEP at 14 weeks (on average). The mice also display deficits in the accelrating rotarod compared to WT mice, indicative of motor dysfunction as seen in patient with EIEE.  The homozygous N1768D mice show an enhance/ accelerated rate of seizure onset and death, indicating a dosage dependent outcome. Lopez-Santiago et al., 2017 showed: Dissociated hippocampal neurons from mutant mice exhibited increased persistent current; recordings from brain slices from mutant mice revealed early after-depolarizations and spontaneous firing in hippocampal neurons","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/25227913","type":"dc:BibliographicResource","dc:abstract":"De novo mutations of the voltage-gated sodium channel gene SCN8A have recently been recognized as a cause of epileptic encephalopathy, which is characterized by refractory seizures with developmental delay and cognitive disability. We previously described the heterozygous SCN8A missense mutation p.Asn1768Asp in a child with epileptic encephalopathy that included seizures, ataxia, and sudden unexpected death in epilepsy (SUDEP). The mutation results in increased persistent sodium current and hyperactivity of transfected neurons. We have characterized a knock-in mouse model expressing this dominant gain-of-function mutation to investigate the pathology of the altered channel in vivo. The mutant channel protein is stable in vivo. Heterozygous Scn8a(N1768D/+) mice exhibit seizures and SUDEP, confirming the causality of the de novo mutation in the proband. Using video/EEG analysis, we detect ictal discharges that coincide with convulsive seizures and myoclonic jerks. Prior to seizure onset, heterozygous mutants are not defective in motor learning or fear conditioning, but do exhibit mild impairment of motor coordination and social discrimination. Homozygous mutant mice exhibit earlier seizure onset than heterozygotes and more rapid progression to death. Analysis of the intermediate phenotype of functionally hemizygous Scn8a(N1768D/-) mice indicates that severity is increased by a double dose of mutant protein and reduced by the presence of wild-type protein. Scn8a(N1768D) mutant mice provide a model of epileptic encephalopathy that will be valuable for studying the in vivo effects of hyperactive Nav1.6 and the response to therapeutic interventions. ","dc:creator":"Wagnon JL","dc:date":"2015","dc:title":"Convulsive seizures and SUDEP in a mouse model of SCN8A epileptic encephalopathy."},"rdfs:label":"Animal Model"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":4,"dc:description":"no changes to open field, sociability or fear conditioning were observed. Given that the mice express a patient derived mutation and fully recapitulate the disease, I will give full points for the model."}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":6},{"id":"cggv:f52993aa-ddee-483d-b15e-dbf21608d5a9_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:f52993aa-ddee-483d-b15e-dbf21608d5a9_ad_other_el","type":"EvidenceLine","evidence":[{"id":"cggv:5eaf214a-175f-4571-88da-38f860bd11df_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:4801a521-22c4-4b2a-9cfa-755dfb6aed32","type":"Proband","ageType":"cggv","ageUnit":"cggv","detectionMethod":"High-throughput targeted sequencing of 65 candidate genes in 500 EIEE cases, using MIP technology","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"no information other than having EIEE was listed. Subjects had refractory seizures and congnitive slowing or regression associated with frequent, onging epiletoform activity.","previousTesting":true,"previousTestingDescription":"negative for 64 other EE causing gene mutations., or genes associated with epilepsy in neurodevelopmental disorders","sex":"Male","variant":{"id":"cggv:5eaf214a-175f-4571-88da-38f860bd11df_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:80543c16-2a3e-4c8c-9492-6c5cdeda42d2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014191.3(SCN8A):c.1984C>T (p.Arg662Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/207108"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/23708187","type":"dc:BibliographicResource","dc:abstract":"Epileptic encephalopathies are a devastating group of epilepsies with poor prognosis, of which the majority are of unknown etiology. We perform targeted massively parallel resequencing of 19 known and 46 candidate genes for epileptic encephalopathy in 500 affected individuals (cases) to identify new genes involved and to investigate the phenotypic spectrum associated with mutations in known genes. Overall, we identified pathogenic mutations in 10% of our cohort. Six of the 46 candidate genes had 1 or more pathogenic variants, collectively accounting for 3% of our cohort. We show that de novo CHD2 and SYNGAP1 mutations are new causes of epileptic encephalopathies, accounting for 1.2% and 1% of cases, respectively. We also expand the phenotypic spectra explained by SCN1A, SCN2A and SCN8A mutations. To our knowledge, this is the largest cohort of cases with epileptic encephalopathies to undergo targeted resequencing. Implementation of this rapid and efficient method will change diagnosis and understanding of the molecular etiologies of these disorders.","dc:creator":"Carvill GL","dc:date":"2013","dc:title":"Targeted resequencing in epileptic encephalopathies identifies de novo mutations in CHD2 and SYNGAP1."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23708187","rdfs:label":"T2657"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.1,"dc:description":"No variant evidence to support dysfunction due to mutation, therefore classified as VUS."},{"id":"cggv:dc95fbdb-9b2c-48e9-9bda-16a59c19b6cc_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:ee1fa4c5-ef41-4cdf-a52f-bcbbf8fdf717","type":"Proband","ageType":"cggv","ageUnit":"cggv","detectionMethod":"High-throughput targeted sequencing of 65 candidate genes in 500 EIEE cases, using MIP technology","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"no information other than having EIEE was listed. Subjects had refractory seizures and congnitive slowing or regression associated with frequent, onging epiletoform activity.","previousTesting":true,"previousTestingDescription":"negative for 64 other EE causing gene mutations., or genes associated with epilepsy in neurodevelopmental disorders","sex":"Male","variant":{"id":"cggv:dc95fbdb-9b2c-48e9-9bda-16a59c19b6cc_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:99e8d7f7-36e7-4e2e-a364-6e0565e67322","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014191.3(SCN8A):c.5615G>A (p.Arg1872Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/253297"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23708187"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23708187","rdfs:label":"T20187"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0,"dc:description":"Given that there is no variant evidence, and a frequency in gnomAD, I will not score pending expert review. There is a chance the one allele found in the Latino population could be a somatic mosaicism. Variant Evidence: Wagnon 2015, functional data."},{"id":"cggv:b7c2d926-3f35-4b9d-98ee-1dd4f93f42e1_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:a57425ce-a5e1-4566-ad65-7279993ac594","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":18,"detectionMethod":"High-throughput targeted sequencing of 65 candidate genes in 500 EIEE cases, using MIP technology","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"EIEE started at 18 months of age.  Part of a large case control, phenotypes included:  EE was defined by refractory seizures and congnitive slowing or regression associated with frequent, ongoing epileptiform activity. Patient H in Larsen et al., 2015: Seizure types experienced focal dyskinesia, myoclonic, status epilepticus and tonic. HAd developmental delay prior to seizures, delayed regression in development following seizure onset. Diagnosed as unclassified EE. HAd ataxia and autistic features","previousTesting":true,"previousTestingDescription":"negative for 64 other EE causing gene mutations., or genes associated with epilepsy in neurodevelopmental disorders","sex":"Male","variant":{"id":"cggv:b7c2d926-3f35-4b9d-98ee-1dd4f93f42e1_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:a93d868f-56f4-49ff-9184-c2836774a376","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014191.3(SCN8A):c.3991C>G (p.Leu1331Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/60709"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23708187"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23708187","rdfs:label":"T3929 and Patient H"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.1,"dc:description":"Because this variant is inherited from a mosaic father it was classified as non-LOF, which requires variant evidence for default points. In the absence of variant evidence the score is for VUS"}],"specifiedBy":"GeneValidityOverallAutosomalDominantOtherVariantEvidenceCriteria","strengthScore":0.2},{"id":"cggv:f52993aa-ddee-483d-b15e-dbf21608d5a9_ad_dn_el","type":"EvidenceLine","evidence":[{"id":"cggv:f9ebda62-2b7e-4570-85a6-29c0c10e9195_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:06ff0f43-c8c3-482d-9e17-6417aed79c4c","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":4,"detectionMethod":"MIP capture of SCN8A and/or Sanger sequencing of SCN8A exons","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"First seizure was tonic with status epilepticus and cyanosis. Other seizure types include generalized tonic-cloni with Status epilepticus, tonic with cyanosis, absence with myoclonic jerks, and epileptic spasms. Development noted as normal prior to seizures and delayed post seizure onset. Severe ID, no speech, loss of eye contact, hypertonia, generalized hyperreflexia, wheelchair bound. Normal MRI at seizure onset and followup. Dx with EIEE. Died at 5yo from SUDEP.","previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"cggv:f9ebda62-2b7e-4570-85a6-29c0c10e9195_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:91212d63-dc5b-438b-9495-0baff4862df6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014191.3(SCN8A):c.5614C>T (p.Arg1872Trp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/207131"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/25568300","type":"dc:BibliographicResource","dc:abstract":"SCN8A encodes the sodium channel voltage-gated Î±8-subunit (Nav1.6). SCN8A mutations have recently been associated with epilepsy and neurodevelopmental disorders. We aimed to delineate the phenotype associated with SCN8A mutations.","dc:creator":"Larsen J","dc:date":"2015","dc:title":"The phenotypic spectrum of SCN8A encephalopathy."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300","rdfs:label":"Patient G"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:81b9ddd7-9fe4-4164-ae49-cc4e57f8b7e2_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:9c089a07-80b6-440b-869b-e7e975bc333e","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"detectionMethod":"WES sequencing","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Exhibited profound developmental delay, intellectual disability and intractable seizures. Myoclonic jerks and sitffness were observed. EEG confirmed hyperekplexia. Seizures began at 2 wo, EEG showed multifocal epileptiform activity, with normal backgroun and normal MRI. Daily tonic and myoclonic seizures continued, with rare tonic-clonic seizures. At 2 yo EEG revealed multifocal epileptiform activity with background slowing, and MRI revealed delayed myelination. Longest seizure-free period was two weekd. Rx with levetiracetam, with addition of phenobarbital, and lacosamide (which showed improement). After increased seizure activity oxcarbazepine was added. At 3 yo, patient is minimally responsive with no obvious dysmorphic features. Profound central hypotonia with some spasticity in the extremities. Patient does not roll over, has complete head lag, and does not fixate or track. Feeding is by gastric tube. Multiple hospital admissions for pneumonia.","previousTesting":true,"previousTestingDescription":"negative for GLRA1, GLRB and MeCP2. Metabolic tests were normal.","sex":"Male","variant":{"id":"cggv:81b9ddd7-9fe4-4164-ae49-cc4e57f8b7e2_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:6c89e34d-8c2d-4c83-a9fb-cce4547b7ead","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014191.3(SCN8A):c.2300C>T (p.Thr767Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/208500"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"Yes","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/24874546","type":"dc:BibliographicResource","dc:abstract":"Rare de novo mutations of sodium channels are thought to be an important cause of sporadic epilepsy. The well established role of de novo mutations of sodium channel SCN1A in Dravet Syndrome supports this view, but the etiology of many cases of epileptic encephalopathy remains unknown. We sought to identify the genetic cause in a patient with early onset epileptic encephalopathy by whole exome sequencing of genomic DNA. The heterozygous mutation c. 2003C>T in SCN8A, the gene encoding sodium channel Nav1.6, was detected in the patient but was not present in either parent. The resulting missense substitution, p.Thr767Ile, alters an evolutionarily conserved residue in the first transmembrane segment of channel domain II. The electrophysiological effects of this mutation were assessed in neuronal cells transfected with mutant or wildtype cDNA. The mutation causes enhanced channel activation, with a 10mV depolarizing shift in voltage dependence of activation as well as increased ramp current. In addition, pyramidal hippocampal neurons expressing the mutant channel exhibit increased spontaneous firing with PDS-like complexes as well as increased frequency of evoked action potentials. The identification of this new gain-of-function mutation of Nav1.6 supports the inclusion of SCN8A as a causative gene in infantile epilepsy, demonstrates a novel mechanism for hyperactivity of Nav1.6, and further expands the role of de novo mutations in severe epilepsy. ","dc:creator":"Estacion M","dc:date":"2014","dc:title":"A novel de novo mutation of SCN8A (Nav1.6) with enhanced channel activation in a child with epileptic encephalopathy."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24874546","rdfs:label":"Proband 1"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2.5,"dc:description":"Variant Evidence: Voltage clamp performed in transfected ND7/23 neuron cell line revealed a 2.5-fold reduction in peak current density for the T761I channels vs. WT. A shift in the Boltzman curve for conduction vs voltage  to the left was observed in the T761I variant vs. WT, indicating hyperpolarization, while the fast-inactivation fit showed no changes. The 10mV shift in voltage suggests signifcantly increased excitability. Response to depolarization revealed a 3-fiold increase in the T761I over WT for average ramp response, further indicating increased channel activity. (Suggesting GOF mutation).Current clamp recording were performed in neonatla rat hippocampal neurons transfected to express T761I and WT SCN8A constructs. Cells expressing the T761I variant exihibt increased spontaneuous activity, suggestive of enhanced channel function. The threshold for the first action potential in T761I expressing cells was 25pA vs 64pA in WT, almost half the threshold. Due to variant evidence provided, I will increase to 2.5 points."},{"id":"cggv:429804b3-2a77-4ffe-85e1-ec652df686a0_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:7274a26f-9481-424f-af1c-03c3b2ce8a2e","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Days","ageValue":1,"detectionMethod":"trio-WES was performed.","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"Born at term by emergency C-section due to fetal hypoxia. Birth weight 4575g and Apgar scores 5/5/6. Seizures present immediately after birth. Intubated and therapeutical hypothermia in general anesthesia for 72 hours was applied, but seizures continued. Once removed from anesthesia, coarse tremor, myoclonias and voice expression appeared in addition to seizures. Seizures were generalized tonic with apnea and bradycardia or focal tonic wtih eye squeezing and mouthing in series up to 60 times per day.Seizures were refractory to treatment. He had central hypotonia with stiffness. No active moevement or head control, eye contact occasional. Dysmorphic facial appearance (high frontal hairline, micrognathia, dysmorphic ears, full cheeks), congenital multiple arthrogryposis, hop dysplasia, inguinal hernia, and hydrocele were present.  Kidney stones were Dx at 7 mo. Patient died at 1 year 5mo due to progressive respiratory failure during respiratory illness. Autopsy refused.MRI's were normal at 9 days old and 1.5 months, but at 5 mo nad 11 mo, mild frontotemporal atrophy and thinning of the corpus callosum, and delay in myelination were described. At 1.75 months, transitory hypogycorrhacia was seen. EM of muscle biopsy showed features of muscle pathology, damaged hyperchromophilic fibers w/ increased lipd deposits and lysosomal enzymes, abnormal mitochondria with loss of inner cristae and inflammation.","previousTesting":true,"previousTestingDescription":"Metabolic tests were normal. GM1- and GM2- gangliosidosis, sailidosis, galatcosialidosis, neuronal ceriod lipofuscinosis-1, and neuronal ceriod lipofuscinosis-2 were excluded by enzymatic analysis. Neuronal transmitter, amino acid and pipecolic acid analysis of CSF were normal. Negative for SLC2A1, POLG, AGCI, and mitochondrial DNA sequncing results.","sex":"Male","variant":{"id":"cggv:429804b3-2a77-4ffe-85e1-ec652df686a0_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:35dcd297-b316-4974-ac71-d4c2370cf9f1","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014191.3(SCN8A):c.3979A>G (p.Ile1327Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/253288"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"Yes","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/24352161","type":"dc:BibliographicResource","dc:abstract":"Epileptic encephalopathies represent a clinically and genetically heterogeneous group of disorders, majority of which are of unknown etiology. We used whole-exome sequencing of a parent-offspring trio to identify the cause of early infantile epileptic encephalopathy in a boy with neonatal seizures, movement disorders, and multiple congenital anomalies who died at the age of 17 months because of respiratory illness and identified a de novo heterozygous missense mutation (c.3979A>G; p.Ile1327Val) in SCN8A (voltage-gated sodium-channel type VIII alpha subunit) gene. The variant was confirmed in the proband with Sanger sequencing. Because the clinical phenotype associated with SCN8A mutations has previously been identified only in a few patients with or without epileptic seizures, these data together with our results suggest that mutations in SCN8A can lead to early infantile epileptic encephalopathy with a broad phenotypic spectrum. Additional investigations will be worthwhile to determine the prevalence and contribution of SCN8A mutations to epileptic encephalopathies. ","dc:creator":"Vaher U","dc:date":"2014","dc:title":"De novo SCN8A mutation identified by whole-exome sequencing in a boy with neonatal epileptic encephalopathy, multiple congenital anomalies, and movement disorders."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/24352161","rdfs:label":"Proband 1"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":0,"dc:description":"No variant evidence to support this missense mutation, so categorized as a VUS. Furthermore, given the dysmorphic features and alternate diagnosis (muscle pathology) from other patients, and a half-sister with epilepsythere is a possiblity of a modifying or combinatorial mutation in the family (maternally), I will reduce points to VUS for this variant pending expert review."},{"id":"cggv:71cc1d7a-d41d-40cc-981d-dd4a2f148ceb_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:38b1cc80-2383-4f16-850c-57d0fc45c934","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":3,"detectionMethod":"MIP capture of SCN8A and/or Sanger sequencing of SCN8A exons","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"First Seizure focal clonic evolving to bilateral convulsive. Other seizure types include statue epilepticus, asymmetric tonic, and atypical absence. Delayed development noted prior to seizure onset, continued delay post seizures onset. Severe ID, quadriparesis with dystonic posturing, dystonic-dyskinateic movement disorder, hypotonia, wheelchair bound.","previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"cggv:71cc1d7a-d41d-40cc-981d-dd4a2f148ceb_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:fd35b4fb-6ef0-47eb-86dc-ea80a1015849","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014191.3(SCN8A):c.4948G>A (p.Ala1650Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/253294"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300","rdfs:label":"Patient N"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:3120f4ec-f372-48fc-b4db-c33901254ebc_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:ed87a3c8-690b-4b17-922a-465294830821","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":4,"detectionMethod":"MIP capture of SCN8A and/or Sanger sequencing of SCN8A exons","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"First seizure was clusters of generalized tonic-clonic. Other seizure types include tonic, focal dyscognitive, focal myoclonic. Development normal prior to sezures and delayed with regression post seizure onset. Moderate ID, speaks short sentences, ataxic gait. MRI normal at onset and followup.","previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"cggv:3120f4ec-f372-48fc-b4db-c33901254ebc_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:6b2f16ef-2a5b-485c-931b-924e01905743","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014191.3(SCN8A):c.779T>C (p.Phe260Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/253279"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300","rdfs:label":"Patient I"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:7ed58862-f7e0-406e-8c6f-aa9ca9c3a7ca_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:1c0eb824-b166-41c5-8b51-ef424c2351bb","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":10,"detectionMethod":"MIP capture of SCN8A and/or Sanger sequencing of SCN8A exons","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"First Seizure clonic alternating. Other seizure types include bilateral convulsive with tonic posture and/or vomiting. Delayed development noted prior to seizure onset, with continued dealy post onset. Severe ID, no speech, loss of eye contact, severe extrapyramidal movement disorder, severe dystrophy, gastroparesis, microcephaly.MRI at 17mo showed normal. Dx with EIEE","previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"cggv:7ed58862-f7e0-406e-8c6f-aa9ca9c3a7ca_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:25249981-40f9-4744-93c5-452f29480cf6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NP_055006.1(SCN8A):p.Pro1428_Lys1473del","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/253289"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300","rdfs:label":"Patient M"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:10ebae17-041e-43a5-aa77-7e973a9dd766_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:65cc7afa-b789-4d46-b62f-f92f43754810","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":2,"detectionMethod":"MIP capture of SCN8A and/or Sanger sequencing of SCN8A exons","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"First seizure was focal clonic. Other seizure types include, clonic, generalized tonic-clonic, atonic, eplipetic spasms, and absence seizures. Tonic, and Focal clonic evolved to bilaterl convulsive seizures. Normal development prior to seizure, but delayed development with regression noted post seizure onset. Severe ID, no speech, loss of eye contact from 2yo on, hypotonia, dystonic cerebral palsy, sterotypies, wheel-chair bound. Normal MRI at onset but at 5yo showed diffuse atrophy.","previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"cggv:10ebae17-041e-43a5-aa77-7e973a9dd766_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:edff8148-5288-40b9-b2e4-5b5d223157f0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014191.3(SCN8A):c.2879T>A (p.Val960Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/253287"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300","rdfs:label":"Patient B"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:daf790d9-14ae-43d1-b2b6-b9594148963f_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:7d17e2e0-1b8c-4b77-95bb-07c44d9c8952","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":1,"detectionMethod":"MIP capture of SCN8A and/or Sanger sequencing of SCN8A exons","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"First seizure prolonged tonic. Other seizure types include focal evolving to bilateral convulsive, myoclonic, tonic-clonic, statue epilepticus, nonconvulsive statue epilepticus. Development noted as normal prior to seizure onset, delayed with regression post seizure. SEvere ID, dystonia, intention tremor with some spaticity.  Normal MRI.","previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"cggv:daf790d9-14ae-43d1-b2b6-b9594148963f_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:91212d63-dc5b-438b-9495-0baff4862df6"},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300","rdfs:label":"Patient Q"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:3d2607e3-3c5c-441e-acb7-9742f964fa97_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:2366c2b0-9875-4aba-98d7-085127d67881","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":4,"detectionMethod":"MIP capture of SCN8A and/or Sanger sequencing of SCN8A exons","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"First seizure was epileptic spasms, and has continued to just be this tpe. Delayed development noted prior to seizures, with ocntinued delayed post seizure onset. Noted with Severe ID. MRI at 5mo showed delayed myelination, residual superficial hemosiderin with frontal predominance. No speech, loss of eye contact, severe hypotonia, secondary microcephaly.","previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"cggv:3d2607e3-3c5c-441e-acb7-9742f964fa97_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:7ba06f50-a6d3-410c-b046-201361794885","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014191.3(SCN8A):c.1228G>C (p.Val410Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/253281"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300","rdfs:label":"Patient L"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:4ae98a88-7655-474e-acfd-b88a51c6c4a4_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:8c9e6cad-174e-4824-954d-0f284830afd0","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":7,"detectionMethod":"MIP capture of SCN8A and/or Sanger sequencing of SCN8A exons","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"No information other than having EIEE was listed. Subjects had refractory seizures and congnitive slowing or regression associated with frequent, onging epiletoform activity. Noted that development was normal prior to seizures, and delayed post seizure onset. Moderate ID, repetitive language, macroencephaly, generalized hyperreflexia, clumsiness, autisitc features.","previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"cggv:4ae98a88-7655-474e-acfd-b88a51c6c4a4_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:99e8d7f7-36e7-4e2e-a364-6e0565e67322"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300","rdfs:label":"Patient D"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":0,"dc:description":"All parents were tested per the materials and methods section. Some patients had maternity and paternity confirmed, but the specific patients with this were not noted. Because this is in ExAC I worry if this is a pentrant variant. This invididuals parents were negative, but nothing was noted of paternity or maternity for this patient. It is in a hotspot AA position, so likely pathogenic, but without previous testing, I will default to experts for scoring."},{"id":"cggv:6aa1f68f-0fcd-453a-ba97-b03cd094a394_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:8bfb7fb8-128c-4d9e-981d-99baac854b3e","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":5,"detectionMethod":"MIP capture of SCN8A and/or Sanger sequencing of SCN8A exons","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"First seizure focal with eye deviation, lip smacking, apnea, perioral cyanosis. Seizure-free for 6 weeks on oxcarbazepine. Normal development prior to seizure, delayed post seizure onset. No mention on intellet, probably due to young age. MRI at 5mo showed mild diffuse white matter volume loss with prominent frontal arachnoid spaces. Noted to have hypotinia.","previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"cggv:6aa1f68f-0fcd-453a-ba97-b03cd094a394_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:d4bda798-5445-45db-9f95-b4d511a7cf8e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014191.3(SCN8A):c.4774G>C (p.Val1592Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/130249"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300","rdfs:label":"Patient P"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:c80b37ac-a359-445f-b12f-a4aff647a7da_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:4577823e-139f-4f17-b41f-ced3d9aa988d","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":3,"detectionMethod":"MIP capture of SCN8A and/or Sanger sequencing of SCN8A exons","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"First seizure(s) focal, generalized tonic-clonic, epileptic spasms with eye deviation. Other seizures types noted focal, tonic, generalized tonic clonic preceded by apnea and deep cyanosis, focal clinoc evolving to bilateral convulsive, generalized, and status epilepticus. Noted as normal developement prior to seizures, but delayed with regression post seizure onset. Severe ID, no speech, loss of eye contact, generalized hypotonia, fatigablemuscle weakness and ptosis, dyskinesia, sterotypic and movements, not sitting, Autistic features. Dx at clinical was Dravt-like. MRI normal at onset, at 15mo showed cerebral atrophy.","previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"cggv:c80b37ac-a359-445f-b12f-a4aff647a7da_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:641bd01e-63f9-4e0c-bf01-8ab23361a652","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014191.3(SCN8A):c.5401C>G (p.Gln1801Glu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/253295"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300","rdfs:label":"Patient C"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:188ec877-4cfd-4bd8-8f58-bd9dc5e16162_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:e0bafe3d-a85a-4160-bc82-99f3ef1917eb","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":6,"detectionMethod":"MIP capture of SCN8A and/or Sanger sequencing of SCN8A exons","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"First Seizure epileptic spasms. Other seizures types include episodes of prolonged staring. Seizure free for 3 years with no treatment. Development noted as normal prior to seizure onset and delayed post seizures. Severe ID, no speech, loss of eye contact, hand stereotypies similar to Rett syndrome but superimposed by general chorea involving arms, legs, and body, wheel-chair boudn.  MRI in infancy noted as normal. Dx with Rett-like syndrome.","previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"cggv:188ec877-4cfd-4bd8-8f58-bd9dc5e16162_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:50307a8d-f375-4e9c-b18f-e95e4ba533f7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014191.3(SCN8A):c.643A>G (p.Asn215Arg)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/253277"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300","rdfs:label":"Patient O"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1,"dc:description":"All parents were tested per the materials and methods section. Some patients had maternity and paternity confirmed, but the specific patients with this were not noted.  Dx with Rett-like syndrome, and seizure-free for 3 years with no treatment, which seems out of line with the SCN8A phenotype alone. I will reduce points pending expert review."},{"id":"cggv:e697019c-9cf2-4d8c-a6d9-c26195cd6a73_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:112e4091-f289-4112-94c4-ce4d8b4d3f70","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":5,"detectionMethod":"MIP capture of SCN8A and/or Sanger sequencing of SCN8A exons","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"At seizure onset had a generalized tonic-clonic seizure during afebrile gastroenteritis. Other seizure types noted are clonic, tonic, atypical absence, and myoclinic. Noted as normal development before seizure onset, with delayed and regression in developemnt post seizure. Severe ID. Normal MRI at onset. No speech, loss of eye contact from 30mo, hypotonia, dystonia, wheelchair-bound. Death at 3yo, from seizure (SUDEP?).","previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"cggv:e697019c-9cf2-4d8c-a6d9-c26195cd6a73_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:cd034e8c-8415-4c8d-a420-aac57b9c687a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014191.3(SCN8A):c.4850G>A (p.Arg1617Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/156106"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300","rdfs:label":"Patient A"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:6eebc59b-5abd-4ee1-890e-7ca04381455d_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:30102173-dc1b-4417-b693-5953c5b29ce7","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Days","ageValue":1,"detectionMethod":"MIP capture of SCN8A and/or Sanger sequencing of SCN8A exons","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"First seizure was nocturanl myoclonic. Other seizure types noted status epilepticus, perioral cyanosis, and tonic. No information on develoment prior to seizures due to onset at 1 day old. Development was delayed, moderate ID, hypotonic, movement disorder. MRI at 2.5mo showed circumscript hypoplasia or corpus callosum.","previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"cggv:6eebc59b-5abd-4ee1-890e-7ca04381455d_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:815eb9ac-072e-4327-bf23-aca8daf33680","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014191.3(SCN8A):c.4435A>G (p.Ile1479Val)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/207120"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300","rdfs:label":"Patient F"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:f298e8f0-37ce-415a-901e-87ca6ddf26f5_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:50469664-8443-4118-b207-3a3b925bb117","type":"Proband","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":6,"detectionMethod":"Peformed CNV microarray (neg), then WGS on quartet, confirmed mutation by Sanger seq.","firstTestingMethod":"Whole genome shotgun sequencing","phenotypeFreeText":"At 6 mo presented with unexplained refractory epilepsy, with early-onset, brief (2-10s) generalized seizures. At 4 yo, seizures changed ot epileptic spasms. She also presented with intellectual disability, developmental delay, hypotonia, and motor and balance coordination deficits. Walked independently at 3 yo, and could speak 5-6 words at 4yo.  Speech regressed after epliletic spasms commensed.  she also developed OCD and repetitive behaviors, which lead to classification of autism (Authors noted no period of normal developemnt was observed in the proband). EEG of initial seizures showed no association with illness of fever and occured up to 40-50 times per day. MRI scans from 6 mo-15yo were normal, and PET scan failed to show any focal abnormalities.  Proband died at 15yo from SUDEP, autopsy showed pulmonary edema and only mild temporal-lobe subpial gliosis.","previousTesting":true,"previousTestingDescription":"WGS was performed. Two compound heterozygous mutations in NRP2 and UNC13C wre found. Authors noted functionally relevant, but neither is associated with disease in humans. Per gnomAD NRP2 R334C= 0.001615, R428W= 1.372e-4 (0.0012 Ashkenazi Jews). UNC13C D304E= 0.005833 (0.04178 A-Jewish).  V2196A= 0.002491 (0.01237 A-Jewish).","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:f298e8f0-37ce-415a-901e-87ca6ddf26f5_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:e855240c-effb-4cdf-876d-aeac7a27ed53","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014191.3(SCN8A):c.5302A>G (p.Asn1768Asp)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/30123"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"Yes","dc:source":"https://pubmed.ncbi.nlm.nih.gov/22365152"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/22365152","rdfs:label":"Proband- N1768D"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":3,"dc:description":"The WGS of the parents  (and sibling) confirmed maternity and paternity through looking at common haplotypes, therefore I can increase the varient evidence points. Variant Evidence: The N1768D variant was cloned into the TTX-resistant NAv1.6. The clones was then transfected into the ND7/23 DRG neuron-derived cell line. Electrophysiological recordings were  performed, and the N1768D expressing cells showed enhanced neuronal excitability, suggesting GoF mechanism for the mutation in SCN8A. Gave maximum points, but question as authors mentioned the NRP2 and UNC13 mutations being contributory, but all the mutations are too high in the general population (gnomAD) to be considered causitive (and most found in homozygous state)."},{"id":"cggv:b9c34415-7da3-4c0e-af36-ca47ee1d8e03_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:e4a6806b-b460-4309-99d6-c10b4e5d3236","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":9,"detectionMethod":"MIP capture of SCN8A and/or Sanger sequencing of SCN8A exons","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"First seizure was nocturanl bilateral convulsive with cyanosis. No other seizure types oted. Seizure-free for 6 months on valporic acid and oxcarbazepine. Development delayed prior to seizure onset, continued delayed post seizures.  Moderate ID, speaks single words, moderate hypotonia, ADHD.","previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"cggv:b9c34415-7da3-4c0e-af36-ca47ee1d8e03_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:6ed54847-31b4-4711-8701-453a83c1900a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_014191.3(SCN8A):c.2668G>A (p.Ala890Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/253286"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/25568300","rdfs:label":"Patient E"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallAutosomalDominantDeNovoVariantEvidenceCriteria","strengthScore":12}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12}],"evidenceStrength":"Definitive","sequence":635,"specifiedBy":"GeneValidityCriteria5","strengthScore":18,"subject":{"id":"cggv:5168975b-cd06-4ffb-aafd-0fda94547bf7","type":"GeneValidityProposition","disease":"obo:MONDO_0100038","gene":"hgnc:10596","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","dc:description":"Approved by the ClinGen Epilepsy Expert Panel 10/20/2017.\n","dc:isVersionOf":{"id":"cggv:f52993aa-ddee-483d-b15e-dbf21608d5a9"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}